[Pharmacokinetic, bacteriological and clinical studies of sultamicillin fine granule in pediatric field]. 1988

H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
Department of Pediatrics, Anjo Kosei Hospital.

Pharmacokinetic, bacteriological and clinical studies on sultamicillin (SBTPC) fine granule were carried out in the field of pediatrics. The results obtained are summarized as follows. 1. Antibacterial activities of SBTPC against clinically isolated strains of Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Staphylococcus aureus, Branhamella catarrhalis, and Escherichia coli were compared with those of ampicillin (ABPC). SBTPC was superior to ABPC especially against beta-lactamase producing H. influenzae, E. coli, S. aureus, and B. catarrhalis. 2. Serum concentrations and urinary excretion rates of sulbactam (SBT) and ABPC after administration of SBTPC fine granule at a dose level of 10 mg/kg in 2 cases were determined. Mean half-lives of SBT and ABPC in the serum following oral administration were about 1.33 and 1.61 hours respectively. Mean urinary recovery rates of SBT and ABPC in 6 hours after oral administration at a dose of 10 mg/kg were 58.7% and 49.6% respectively. 3. SBTPC fine granule was administered to 20 pediatric patients with various bacterial infections (pneumonia 8 cases, bronchitis 2, pharyngitis 2, tonsillitis 4, subcutaneous abscess 1 and urinary tract infection 3). The overall clinical efficacy rate was 100% and the overall bacteriological eradication rate was 75%. 4. No adverse reactions were observed except 1 case of loose stool. No abnormal laboratory test values were observed. These results indicate the usefulness of SBTPC fine granule in the treatment of bacterial infections in children.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
December 1988, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
December 1988, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
December 1988, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
December 1988, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
September 1995, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
December 1988, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
December 1988, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
February 1995, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
December 1988, The Japanese journal of antibiotics,
H Ishikawa, and H Takeuchi, and H Kimura, and F Hayakawa, and N Yamamoto, and Y Nakao, and K Kuno
February 1989, The Japanese journal of antibiotics,
Copied contents to your clipboard!